Disc Medicine reports trial win for sun-allergy pill, shares jump 35%
Disc Medicine's experimental bitopertin helped rare-disease patients stay in sunlight longer without pain. The company plans to resubmit to the FDA.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Disc Medicine said on Monday that its experimental pill for a rare blood disorder let patients spend more time in sunlight without pain, according to Reuters. Its shares rose 35% in early trading.
Bitopertin is being developed for erythropoietic protoporphyria, an inherited disorder in which protoporphyrin IX builds up in the blood and makes skin extremely sensitive to light. In the trial of 183 patients aged 12 and older, drug takers had 41.4% lower PPIX levels than placebo users, and in the sixth month they gained 12.2 more pain-free hours per month in sunlight.
The FDA had earlier rejected the drug, citing an unclear link between lower protoporphyrin levels and sunlight tolerance. Disc plans to submit the new data by year-end, with a possible launch around mid-2027.
why it matters
For markets this is a single-company story, but it matters to biotech investors because the trial win lowers the risk of another rejection. Truist's analyst sees limited remaining uncertainty over approval, while BMO estimates peak sales of $1.7 billion.
market impact
Disc Medicine shares: the trial win and planned FDA resubmission support the company's stock
tags
instruments
sources
- Disc Medicine's late-stage win clears path for approval of sun-allergy pill — Reuters, 19 October 2026 at 16:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗